New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
New solvent-free micronization technology expanded at the Darmstadt site in Germany
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Sales reflect continued strong growth in oncology and vaccines
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
Subscribe To Our Newsletter & Stay Updated
